Immunotherapy against amyloid-β(Aβ) may improve rodent cognitive function by reducing amyloid neuropathology
and is being validated in clinical trials with positive preliminary results. However, for a complete understanding
of the direct and long-term immunization responses in the aged patient, and also to avoid significant side effects, several
key aspects remain to be clarified. Thus, to investigate brain Aβ clearance and Th2 responses in the elderly, and the reverse
inflammatory events not found in the immunized rodent, better Alzheimer’s disease (AD) models are required. In
the aged familiar canine with a Cognitive Dysfunction Syndrome (CDS) we describe the rapid effectiveness and the full
safety profile of a new active vaccine candidate for human AD prevention and treatment. In these aged animals, besidesa
weak immune system, the antibody response activated a coordinated central and peripheral Aβ clearance, that rapidly improved
their cognitive function in absence of any side effects. Our results also confirm the interest to use familiar dogs to
develop innovative and reliable therapies for AD.
Keywords: Aβ, Alzheimer’s disease, amyloid vaccine, canine cognitive dysfunction syndrome, immunotherapy, dog.
Rights & PermissionsPrintExport